KYORIN Pharmaceutical Hits Day Low at JPY 1,361 Amid Price Pressure

KYORIN Pharmaceutical Co., Ltd. has experienced significant volatility today, with the stock hitting an intraday low of JPY 1,361.00, reflecting a decline of -10.96%. This drop is part of a broader trend, as the stock has underperformed against the Japan Nikkei 225 index, which has gained 0.84% on the same day. Over the past week, KYORIN has seen a decrease of -10.09%, and its performance over the last month shows a decline of -17.09%. Despite these short-term challenges, the company has reported a notable increase in net profit for the nine months ending March 2025, growing by 62.61%. The return on capital employed (ROCE) has reached a high of 8.01%, and raw material costs have decreased by 1.94% year-over-year. However, the stock's long-term growth remains a concern, with net sales growing at an annual rate of only 4.62% over the past five years. With a market capitalization of JPY 92,496 million, KYORIN's current price-to-earnings ratio stands at 9.00, indicating a valuation that is attractive compared to its peers. Nonetheless, the stock's consistent underperformance against the benchmark over the last three years highlights ongoing challenges for the company in the competitive pharmaceuticals and biotechnology sector.